MX2016000293A - Biomarcadores del trastrono del espectro autista. - Google Patents

Biomarcadores del trastrono del espectro autista.

Info

Publication number
MX2016000293A
MX2016000293A MX2016000293A MX2016000293A MX2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A MX 2016000293 A MX2016000293 A MX 2016000293A
Authority
MX
Mexico
Prior art keywords
autism
metabolites
spectrum disorder
metabolic signatures
autism spectrum
Prior art date
Application number
MX2016000293A
Other languages
English (en)
Inventor
Alan Smith
Paul West
Robert E Burrier
Laura Egnash
Preeti Bais
Original Assignee
Stemina Biomarker Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemina Biomarker Discovery Inc filed Critical Stemina Biomarker Discovery Inc
Publication of MX2016000293A publication Critical patent/MX2016000293A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En la presente se describen métodos para identificar improntas metabólicas en el plasma sanguíneo que son exclusivas del autismo. Las muestras son analizadas mediante diversas técnicas basadas en espectrometría de masas-cromatografía para medir ortogonalmente una amplia variedad de metabolitos de peso molecular pequeño producidos diferencialmente en muestras de pacientes autistas versus muestras de controles no autistas. Estos metabolitos individuales o un panel de los metabolitos sirven como improntas metabólicas del autismo. Las improntas metabólicas se utilizan en métodos diagnósticos para identificar con exactitud a los individuos que padecen de trastornos del espectro autista (TEA).
MX2016000293A 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista. MX2016000293A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844128P 2013-07-09 2013-07-09
US201461996835P 2014-05-14 2014-05-14
PCT/US2014/045397 WO2015006160A2 (en) 2013-07-09 2014-07-03 Biomarkers of autism spectrum disorder

Publications (1)

Publication Number Publication Date
MX2016000293A true MX2016000293A (es) 2016-06-21

Family

ID=52280698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000293A MX2016000293A (es) 2013-07-09 2014-07-03 Biomarcadores del trastrono del espectro autista.

Country Status (6)

Country Link
US (2) US10060932B2 (es)
EP (1) EP3019624B1 (es)
JP (1) JP6763770B2 (es)
CA (1) CA2917483A1 (es)
MX (1) MX2016000293A (es)
WO (1) WO2015006160A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
WO2017197252A1 (en) * 2016-05-13 2017-11-16 Stemina Biomarker Discovery, Inc. Autism subsets
WO2018183986A1 (en) 2017-03-31 2018-10-04 Axial Biotherapeutics, Inc. Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
EP3746796A4 (en) * 2018-01-29 2021-12-22 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISORDERS BASED ON METABOTYPES CONTAINING AN AMINE
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
EP3948275A4 (en) * 2019-04-05 2023-05-24 Arizona Board of Regents on behalf of Arizona State University DIAGNOSIS OF CHILDREN'S RISK FOR AUTISTIC SPECTRUM DISEASE
CN113906296A (zh) * 2019-04-23 2022-01-07 中国医学科学院北京协和医院 基于机器学习的使用代谢物作为标记物的孤独症谱系障碍诊断方法和装置
EP3963323A4 (en) * 2019-05-02 2023-05-31 Stemina Biomarker Discovery, Inc. DIAGNOSIS AND TREATMENT OF AUTISTIC SPECTRUM DISEASES RELATED TO ALTERED METABOLIC PATHWAYS
US20220146527A1 (en) * 2019-09-17 2022-05-12 Chang Gung University Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms
WO2021072351A1 (en) * 2019-10-11 2021-04-15 Stemina Biomarker Discovery, Inc. Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations
WO2021076960A1 (en) * 2019-10-16 2021-04-22 Anand Rene Live virus vaccine injury risk
WO2022056646A1 (en) * 2020-09-21 2022-03-24 Molecular You Corporation Method of diagnosis and treatment of autism spectrum disorder
CN113125588B (zh) * 2021-03-17 2022-01-14 广东省农业科学院农业质量标准与监测技术研究所 一种代谢组学分析技术判别鸭屎香单丛茶时空分类的应用
KR102530345B1 (ko) * 2021-08-04 2023-05-10 단국대학교 천안캠퍼스 산학협력단 대사체 프로파일링을 이용한 자폐 스펙트럼 장애의 진단용 조성물 및 이를 포함하는 진단키트

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6708064B2 (en) * 2000-02-24 2004-03-16 Ali R. Rezai Modulation of the brain to affect psychiatric disorders
WO2001079837A1 (en) 2000-04-12 2001-10-25 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
CA2443806A1 (en) 2000-04-14 2002-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US20080154332A1 (en) * 2001-12-24 2008-06-26 The Cleveland Clinic Foundation Modulation of the Brain to Affect Psychiatric Disorders and Functions
US8131473B1 (en) 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
US7604948B2 (en) * 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20070023677A1 (en) 2005-06-29 2007-02-01 Perkins Patrick D Multimode ionization source and method for screening molecules
CA2618123C (en) 2005-08-08 2013-04-02 Metabolon Inc. A system, method, and computer program product using a database in a computing system to compile and compare metabolomic data obtained from a plurality of samples
US7949475B2 (en) 2005-08-08 2011-05-24 Metabolon Inc. System and method for analyzing metabolomic data
JP5496650B2 (ja) 2006-03-21 2014-05-21 メタボロン インコーポレイテッド サンプル内の個々の要素を識別及び定量化するために分光測定データを分析するシステム、方法及びコンピュータプログラム製品
US20110229883A1 (en) 2007-04-10 2011-09-22 Bernd Spur Biochemical Markers for Disease States and Genes for Identification of Biochemical Defects
US8273575B2 (en) 2007-07-26 2012-09-25 Phenomenome Discoveries Inc. Methods for the diagnosis, risk assessment, and monitoring of autism spectrum disorders
WO2009032722A1 (en) * 2007-08-29 2009-03-12 The Cleveland Clinic Foundation Carbamylated proteins and risk of cardiovascular disease
US7884318B2 (en) 2008-01-16 2011-02-08 Metabolon, Inc. Systems, methods, and computer-readable medium for determining composition of chemical constituents in a complex mixture
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
DK200970026A (en) 2009-06-12 2010-12-13 Alfa Laval Corp Ab A centrifugal separator
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
DK2550365T3 (en) * 2010-03-22 2018-09-10 Stemina Biomarker Discovery Inc PREVENTION OF HUMAN DEVELOPMENTAL TOXICITY OF MEDICINAL PRODUCTS USING HUMAN STEM CELL-LIKE CELLS AND METABOLOMICS
WO2011139914A1 (en) 2010-04-29 2011-11-10 Wisconsin Alumni Research Foundation Metabolic biomarkers of autism
WO2011146683A1 (en) * 2010-05-19 2011-11-24 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
WO2013086365A2 (en) * 2011-12-09 2013-06-13 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same
CN104768560A (zh) * 2012-08-29 2015-07-08 加州理工学院 孤独症谱系障碍的诊断和治疗
EP2897614A4 (en) 2012-09-21 2016-04-13 Univ Toronto CMPF ACID AS A BIOMARKER FOR DIABETES AND ASSOCIATED METHODS
EP2914748B1 (en) * 2012-11-02 2019-03-13 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
JP6404834B2 (ja) * 2013-01-31 2018-10-17 メタボロン，インコーポレイテッド インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
US20150294081A1 (en) * 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) * 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk

Also Published As

Publication number Publication date
EP3019624A4 (en) 2017-01-11
JP6763770B2 (ja) 2020-09-30
CA2917483A1 (en) 2015-01-15
EP3019624B1 (en) 2020-09-16
JP2016530504A (ja) 2016-09-29
WO2015006160A2 (en) 2015-01-15
US11268966B2 (en) 2022-03-08
EP3019624A2 (en) 2016-05-18
US10060932B2 (en) 2018-08-28
US20160169915A1 (en) 2016-06-16
US20190072569A1 (en) 2019-03-07
WO2015006160A3 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
MX2016000293A (es) Biomarcadores del trastrono del espectro autista.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
GB2519906A (en) Methods and systems for detecting biological components
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EP4234583A3 (en) Evaluation and treatment of bradykinin-mediated disorders
EP3865135A3 (en) Neuroactive steroids for use in therapy
BR112014010955A2 (pt) sistema e método para processar amostras
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
BR112015019326A2 (pt) dispositivo de registro de amostragem e armazenamento para análise de gás respiratório
NZ618062A (en) Hsp90 combination therapy
BR112016010510A2 (pt) método, arranjo e uso do mesmo
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
IN2014MN02101A (es)
IN2014DE01077A (es)
EP4220170A3 (en) Method for detecting a solid tumor cancer
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2013167727A3 (en) Method for determining arthritis relapse risk
EA201300600A1 (ru) Способ диагностики соединительной ткани и его применение
BR112015027249A2 (pt) método de diagnóstico de câncer
GB201102693D0 (en) Method for identifying neonates at risk for necrotizing enterocolitis
WO2016118920A3 (en) Metabolomic based biomarkers for colon cancer detection